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Human T lymphocytes stimulated with phytohaemagglutinin undergo a single round of cell division. Fur- 
ther proliferation is dependent on the lymphokine interleukin-2 (IL2) [(1987) Immunology 60, 7-121. We 
show here that binding of IL2 to its receptors on the lymphocyte surface triggers the generation of cyclic 
AMP. In contrast, generation of inositol phosphates from the breakdown of inositol lipids was not detected. 
We suggest that cyclic AMP may play a role in the transduction of the IL2 proliferative signal in T Iympho- 
cytes. 
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1. INTRODUCTION 
The binding of the lymphokine interleukin-2 
(IL2) to specific cell-surface receptors present on 
activated T lymphocytes triggers DNA synthesis 
and mitogenesis in these cells [ 11. The IL2 receptor 
has recently been shown to consist of two non- 
sulfhydryl linked transmembrane polypeptides 
with molecular masses of 75 and 55 kDa, respec- 
tively [2]. Nevertheless, the mechanisms involved 
in transduction of the IL2 mitogenic signal are 
unclear. The binding of some mitogens to their 
cognate cell-surface receptors stimulates the 
generation of biochemical second messengers 
within target cells. These second messengers ac- 
tivate cellular phosphotransferase systems, which 
are presumed to initiate cascades of biochemical 
reactions which culminate in DNA synthesis and 
cell division [3-51. For example, binding of the 
mitogen prostaglandin Ei to its receptor on Swiss 
3T3 fibroblasts results in the elevation of cyclic 
AMP (CAMP) [6], the allosteric activator of 
CAMP-dependent protein kinase [7]. In contrast, 
PDGF binding to cells triggers the breakdown of 
inositol-containing phospholipids with the genera- 
tion of a pair of second messengers, diacylglycerol 
(DG) and inositol trisphosphate (IP3) [8]. DG is an 
allosteric activator of protein kinase C, while IP3 
stimulates release of Ca 2+ from intracellular stores 
and consequent activation of calmodulin- 
dependent protein kinases [9,10]. Since IL2 
stimulation of T lymphocytes rapidly stimulates 
protein phosphorylation [l 1,121, we measured the 
generation of second messengers in IL2-dependent 
lymphocytes. While increase in CAMP levels were 
clearly detectable, we found no evidence for the 
breakdown of inositol lipids following IL2 
binding. 
2. MATERIALS AND METHODS 
Correspondence address: R.G. Wickremasinghe, 2.1. Lymphocyte preparations 
Department of Haematology, Royal Free Hospital, Lymphocytes were prepared by sedimentation of 
Pond Street, Hampstead, London NW3 2QG, England heparinized venous blood from normal donors on 
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Lymphoprep gradients (Nyegaard, Oslo). Mono- 
cytes and platelets were removed and the lympho- 
cytes activated by treatment for 5 days with 
10~l~mll’ PHA (Wellcome, Beckenham). The ac- 
tivated lymphocytes were completely dependent on 
exogenous IL2 for further proliferation [13]. 
2.2. Cyclic AMP measurement 
For CAMP measurements, cells were resuspend- 
ed at 5 x lo6 ml-’ in fresh RPM1 1640 plus 10% 
fetal calf serum and allowed to equilibrate at 37°C 
5% CO2 for 1 h. Recombinant human IL2 (10 
units - ml- ‘, Amersham) or its vehicle were then 
added. At various times cells were harvested by 
centrifugation at 800 x g for 3 min and CAMP ex- 
tracted by addition of 0.5 ml ice-cold ethanol 
followed by sonication for 30 s. Radioim- 
munoassay was carried out using a rabbit an- 
tiserum against succinyl CAMP (Miles Laborato- 
ries, Stoke Poges) by a protocol supplied by the 
manufacturer. 
2.3. Generation of inositol phosphates 
Resting lymphocytes (5 x lo6 ml-’ were labelled 
for 18 h at 37°C with 2.5 &i.rnll’ myo-[3H]ino- 
sitol (Amersham) in RPM1 1640 medium without 
inositol, supplemented with 10% dialyzed calf 
serum and antibiotics. Activated lymphocytes were 
labelled in the same medium at 10’ cells .rnll’ for 
4 h. (Labelling in inositol-free medium did not im- 
pair the ability of lymphocytes to respond to ap- 
propriate mitogens.) Labelled cells were washed 
twice in Hanks’ salts, resuspended in unlabelled 
medium (2 x lo6 cells. ml-‘) and incubated at 
37°C for 1 h in order to deplete free myo-[3H]ino- 
sitol. They were then resuspended at 10’ cellsOml-’ 
in RPM1 1640 (without serum). Following a 20 min 
incubation at 37°C the appropriate mitogen or its 
vehicle was added. Inositol phosphates were ex- 
tracted as described [14] and the radiolabel in in- 
dividual inositol phosphates was determined by 
chromatography on Dowex Al-X8 columns [ 151. 
Recovery of the radiolabel following analysis was 
typically 85-90%. 
3. RESULTS AND DISCUSSION 
We have recently shown that monocyte-depleted 
resting human lymphocytes undergo a single 
IL2-independent cell division when stimulated with 
phytohaemagglutinin (PHA) [ 131. The resulting 
daughter cells (activated cells) were completely 
dependent on exogenous IL2 for further prolifera- 
tion. We have used these activated lymphocytes to 
measure the generation of second messengers 
following IL2 treatment. Fig.1 shows that the 
basal levels of CAMP in activated lymphocytes 
from different donors showed considerable 
variability. However, addition of IL2 to these cells 
resulted in an increase in CAMP levels of 
1.6-2.3-fold 30 min following growth factor addi- 
tion. Fig.2 shows the time course of this CAMP 
elevation. A detectable increase was seen 3.5 min 
following IL2 addition with maximal levels be- 
tween 20 and 30 min. A similar time course of 
CAMP elevation was observed in two further ex- 
periments. 
We then assayed the generation of the soluble 
inositol phosphates following 5 min incubation of 
activated lymphocytes with IL2. In this experiment 
the lymphocytes were pre-labelled with myo- 
[3H]inositol to label the inositol-containing 
1 
Fig. 1. Increase of CAMP levels in activated lymphocytes 
treated with IL2. CAMP levels in untreated (open bars) 
and IL2 treated (hatched bars) activated lymphocytes 
from different donors. Assays were carried out in 
triplicate. Bars indicate standard errors. The IL2 
stimulated increases in CAMP levels were significant 
(P < 0.001, Student’s t-test). 
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Fig.2. Time course of increase of CAMP in activated 
lymphocytes treated with 10 units. ml- ’ IL2 at time zero. 
(0) Control; (0) IL2. Assays were carried out in 
duplicate. 
phospholipids [ 141. The small (1.3-fold) increase in 
inositol phosphate (IP) evident here was not 
reproduced in other experiments (fig.3A). No in- 
crease in inositol bisphosphate (IP2) or inositol 
trisphosphate (IP3) was evident. The latter ob- 
servation is significant, since IP3 is the initial 
breakdown product of phosphatidylinositol 
bisphosphate (PIPz), which is thought to be the 
key substrate in ligand-stimulated inositol lipid 
breakdown [9,10]. As a positive control we also 
assayed the generation of labelled inositol 
phosphates from myo-[3H]inositol pre-labelled 
resting lymphocytes following PHA stimulation. 
In agreement with earlier reports [16,17], increases 
in levels of IP, IP2 and IP3 were detectable. The 
largest increase was in radiolabelled IP3 (3-fold) 
(fig.3B). The overall increase in soluble inositol 
phosphates stimulated by PHA was 1.7-fold, 
whereas no overall increase was observed follow- 
ing IL2 stimulation of activated cells (fig.3A). 
The addition of 10 mM LiCl to cell cultures 
causes an inhibition of breakdown of IP to in- 
ositol. This inhibition has been exploited to 
facilitate detection of inositol phosphate produc- 
tion, since the sequential breakdown of IP3 via IPz 
and IP is blocked, with consequent accumulation 
of high levels of IP [14]. The experiment depicted 
in fig.4A shows that no significant accumulation 
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Fig.3. Changes in levels of radiolabelled inositol 
phosphates following IL2 treatment of myo-[‘Hlinositol 
pre-labelled, activated lymphocytes (A) or PHA 
treatment of resting lymphocytes (B). Open bars, 
control; hatched bars, mitogen added 5 min before 
extraction. Figures above each pair of bars give the ratio 
of radiolabel in each inositol phosphate from mitogen- 
treated cells compared to the control. 
[3H]inositol pre-labelled, LiCl-treated, activated 
lymphocytes were treated for 30 min with IL2. In 
contrast, a very large increase in IP, accompanied 
by smaller increases in IPz and IP3 was clearly evi- 
dent when resting lymphocytes were treated with 
PHA (fig.4B). The difference could not be at- 
tributed to different levels of labelling of inositol 
lipids in resting and activated cells; in the experi- 
ment shown here the resting cells contained 
5664 dpm/ 10” cells and the activated cells 
4320 dpm/106 cells respectively in inositol lipids, 
as measured by scintillation counting of the 
organic phase residues following inositol 
Fig.4. Changes in levels of radiolabelled inositol 
phosphates following IL2 treatment of myo-[3H]inositol 
labelled activated lymphocytes (A) or resting 
lymphocytes (B) in the presence of 10 mM LiCI. See 
legend to fig.3 for details. 
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phosphate extraction. Results very similar to those 
depicted in fig.4A and B were obtained on four 
further occasions, confirming that inositol lipid 
breakdown was a consequence of PHA treatment 
of resting lymphocytes but not of IL2 binding to 
activated lymphocytes. 
The results described here show that binding of 
mitogenic levels of IL2 to cell surface receptors of 
activated T lymphocytes stimulates elevation of 
cellular CAMP. The IL2-stimulated CAMP eleva- 
tion observed here is slower than the increases 
elicited by acute hormones. This time course is, 
however, compatible with the observation that IL2 
binding reaches equilibrium at about 15 min [ 181 
and is comparable with the time course of CAMP 
elevation in Swiss 3T3 cells treated with platelet- 
derived growth factor [19]. Accordingly, we sug- 
gest that CAMP elevation contributes to the 
mechanism by which the IL2 proliferation signal is 
transduced in activated T lymphocytes. We have 
been unable to stimulate cell proliferation by addi- 
tion of agents which increase CAMP levels, e.g. 
dibutyryl CAMP, isobutylmethylxanthine (not 
shown) suggesting that other transducing mech- 
anisms may also contribute to securing commit- 
ment to mitosis. However, no breakdown of 
inositol lipids was observed, in agreement with 
observations on cloned murine cytotoxic lym- 
phocytes [20] and on human short-term lymphoid 
cell lines [21]. This is in contrast with the con- 
clusions of Farrar and co-workers [22,23] who 
showed that IL2 stimulation of the murine CT6 
cytotoxic T-cell line triggered the breakdown of in- 
ositol lipids [22] and the translocation of protein 
kinase C from the cytosol to the particulate frac- 
tion [23], presumably resulting from its activation 
by DG generated from inositol lipids. Beckner and 
Farrar [24] have shown that IL2 actually reduces 
CAMP levels in CT6 cells, thereby reversing the an- 
tiproliferative effect of CAMP levels produced by 
prostaglandin treatment. Furthermore, activation 
of protein kinase C was required for the IL2-in- 
duced reduction in CAMP levels, suggesting a 
reciprocal relationship between the CAMP-de- 
pendent kinase system and protein kinase C. In 
contrast, protein kinase C activation causes CAMP 
elevation in lymphomas [25]. In order to reconcile 
these observations we suggest that the IL2 receptor 
may be coupled to different intracellular second 
messenger generating systems in different cell 
types. Both the generation of CAMP by adenylate 
cyclase [26] and the breakdown of inositol phos- 
pholipids [27] appears to be coupled to receptor 
stimulation via GTP binding proteins (G proteins). 
The IL2 receptor of CT6 cells has recently been 
shown to be coupled to a G protein [28]. It is 
therefore plausible that the association of the IL2 
receptor with different G proteins in different con- 
texts may stimulate the generation of different 
second messengers and the activation of alternative 
phosphotransferase systems. This is in accord with 
the observations that epidermal growth factor 
stimulates polyphosphoinositide breakdown in 
A431 cells [29] but not in hamster fibroblasts [30]. 
Therefore, the same growth factor may stimulate 
mitogenesis via alternative second messenger 
systems. 
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